Company

TiGenix NV (Euronext Brussels and Nasdaq: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.

 

Two products from the adipose-derived stem cell technology platform are currently in clinical development.

 

- Cx601 has successfully completed a Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients. On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States.

 

- Cx611 has completed a European Phase I safety trial and is currently preparing to initiate a Phase I/II clinical trial in severe sepsis in Europe in the fourth quarter of 2016.

 

Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI).

 

In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication.

 

TiGenix is based in Leuven, Belgium, and has operations in Madrid, Spain.



Read more...

Products

Products

Read more...

Latest News

17 February 2017 - Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn’s Disease Patients with Cx601 (EN - NL - FR)

6 February 2017 - TiGenix announces acceptance of Cx601 abstract for oral presentation at 12th Congress of ECCO (EN - NL - FR)

31 January 2017 - TiGenix Enrolls First Patient in Phase Ib/IIa Clinical Trial of Cx611 in Severe Sepsis (EN - NL - FR)

9 January 2017 - Transparency notification (EN - NL)

29 December 2016 - Transparency Information (EN - NL)

Read more...

Company slide deck

2017 - Corporate Presentation

Management presentations

Presentation Brussels, 6 February 2017

Nasdaq CEO Signature Series Interview with Eduardo Bravo

First Half 2016 Business and Financial Update

ECCO Plenary ADMIRE-CD presentation

TiGenix ECCO Symposium presentations

Interview with De Tijd, 23 September 2015

Mediafin Investor Night (ENG - FR), 23 September 2015

HY15 results webcast presentation 15 September 2015

1H 2015 results webcast recording, September 2015

TiGenix Cx601 ADMIRE-CD Top-Line Results Webcast, August 2015

Tigenix at Alliance for Regenerative Medicine Conference, March 2015

TiGenix on Kanaal Z television, November 2014